NRG-GU005

Closed to Accrual

Return to Protocol Table

Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer

Principal Investigator

Rodney Ellis, MD

Status

Closed to Accrual

Date Opened To Accrual

November 16 2017

Date Closed to Accrual

June 08 2022

Disease Site

Genitourinary [GU]

Prostate

Phase

III

Developmental Therapeutics

Primary Objective

To determine whether SBRT can be shown to be superior to hypofractionated IMRT in terms of GU and GI toxicity by having fewer patients that experience a minimal important decline (MID) in urinary irritation/obstructive and bowel HRQOL as measured by EPIC-26 at 24 months post completion of therapy.
To determine if SBRT (5 fractions of 7.25 Gy) is superior to hypofractionated IMRT (28 fractions of 2.5 Gy) as measured by Disease Free Survival (DFS)

Patient Population

Patients with previously untreated localized intermediate-risk prostate cancer

Target Accrual

692

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.